These findings further implicate RORγ agonism as a potential therapeutic strategy not only to enhance protective anti-tumor immunity by increasing IL-17 expression but also attenuating immunosuppressive action through PD-1 stimulation with one compound in clinical development for cancer therapy (Hu et al., 2016; Wilkins et al., 2017). The gene discussed is RORC; the disease is cancer.